Pharma Rally Still Has Steam? Kranthi Bathini On Cipla, Sun Pharma & More

The pharma sector has delivered a strong rally, but is the momentum still intact? Kranthi Bathini, Director of Research, WealthMills Securities, believes the pharma and healthcare story still has room to run. In this conversation, he explains why any consolidation or decline in pharma stocks could offer an opportunity for medium- to long-term investors. The discussion comes as Cipla, Sun Pharma, Piramal Pharma and Aurobindo Pharma remain in focus on company-specific developments. Cipla faces a regulatory issue, while Sun Pharma gets a positive update on its alopecia drug Lixxelvi. Piramal Pharma's Bayer arrangement ends in December, while Aurobindo Pharma has multiple growth triggers. Bathini says the recent knee-jerk reactions should be viewed as short-term sentiment moves and believes pharma stocks still have significant steam left for investors with a longer-term horizon.